Credit score: Pixabay from Pexels
The next weekly dose of semaglutide (7.2 mg) can considerably enhance weight reduction and associated well being outcomes in adults dwelling with weight problems, together with these with sort 2 diabetes (T2D), in response to the outcomes of two large-scale, worldwide section 3 scientific trials.
The findings, revealed in The Lancet Diabetes & Endocrinology journal, counsel {that a} larger dose of semaglutide provides a promising new possibility for folks with weight problems, together with these with T2D, who haven’t achieved adequate weight reduction with current therapies.
The STEP UP and STEP UP T2D scientific trials are the primary to analyze whether or not rising the dose of semaglutide from the presently accredited dose of two.4 mg to 7.2 mg is secure and results in further weight discount. Trial contributors have been randomized to obtain both the upper 7.2 mg dose of semaglutide, the presently accredited 2.4 mg dose, or placebo over 72 weeks. All contributors—no matter therapy group—acquired way of life interventions resembling dietary counseling and elevated bodily exercise suggestions.
In adults with out diabetes, a 7.2 mg dose of semaglutide led to a mean weight lack of practically 19%, surpassing the 16% loss seen with 2.4 mg and 4% with placebo. Practically half of the contributors on the upper dose misplaced 20% or extra of their physique weight, with about one-third shedding not less than 25%. Individuals additionally skilled enhancements in waist circumference, blood strain, blood sugar, and levels of cholesterol, all key components in lowering obesity-related well being dangers.
Equally, in adults with weight problems and T2D, the 7.2 mg dose resulted in a mean 13% weight reduction in comparison with 10% with 2.4 mg and three.9% with placebo, together with vital reductions in blood sugar ranges and waist measurement.
Each trials reported that the upper dose of semaglutide was secure and customarily properly tolerated. Gastrointestinal unintended effects like nausea and diarrhea, and a few sensory signs like tingling, have been the most typical. Nevertheless, most unintended effects have been manageable, resolved over time, and didn’t result in contributors dropping out of the trial. No improve in critical adversarial occasions or extreme hypoglycemia was noticed with the upper dose.
By delivering higher weight discount and metabolic advantages whereas sustaining a positive security profile, the authors say this larger dose might assist extra folks attain their well being targets and cut back the burden of obesity-related issues worldwide. Nevertheless, they spotlight that additional analysis is required to totally perceive the long-term advantages and dangers.
Extra data:
Every day steps and well being outcomes in adults: a scientific evaluate and dose-response meta-analysis, The Lancet Diabetes & Endocrinology (2025). DOI: 10.1016/S2213-8587(25)00226-8
Quotation:
Larger doses of semaglutide can safely improve weight reduction for adults dwelling with weight problems, scientific trials affirm (2025, September 14)
retrieved 14 September 2025
from https://medicalxpress.com/information/2025-09-higher-doses-semaglutide-safely-weight.html
This doc is topic to copyright. Other than any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for data functions solely.
